期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨3d方案治疗骨髓增生异常综合征疗效讨论附两例病例报道 被引量：7

Discussion of decitabine 3-day program treatment on myelodysplastic syndrome——report of 2 cases
下载PDF
导出
摘要 地西他滨作为治疗骨髓增生异常综合征(MDS)的推荐用药,目前有3 d和5 d两种方案。3 d方案剂量较大,人们对其安全性存在担忧。我院近期对2例老年MDS患者进行了地西他滨3 d方案的治疗,安全性较好。 As the recommended treatment for myelodysplastic syndrome（MDS）,there were two kinds of programs： 3-day and 5-day.There was concern about the safety of decitabine 3-day program because of its larger dose.Recently,we took the 3-day program of decitabine treatment on two elderly MDS patients safely.
作者 宋慧慧 陈宝安 刘苒 高冲 丁家华 孙耘玉 王骏 程坚 赵刚 余正平 鲍文
机构地区 东南大学附属中大医院血液科
出处 《东南大学学报（医学版）》 CAS 2011年第3期474-477,共4页 Journal of Southeast University(Medical Science Edition)
基金 "十一五"国家科技支撑计划课题(2008BAI61B02)
关键词 地西他滨 3d方案 骨髓增生异常综合征 病例报告 decitabine 3-day program myelodysplastic syndrome case report
分类号 R733.3 [医药卫生—肿瘤] R453 [医药卫生—治疗学]
  • 相关文献

参考文献9

二级参考文献17

  • 1夏瑞祥,蔡学杰.地西他滨在恶性血液病中的作用[J].安徽医药,2006,10(12):900-901. 被引量：4
  • 2SorianoA,Chamolin R, Mccormick G, et al. Maintenance therapy with 5 - agacitidine after allogenneic stem all transplantation for acutem ydogenous leukemia and high - risk myelodysplastic syndrome a dese and schedule finding study. Blood, 2005, 108 (1): 104.
  • 3Soriano A, Braitah F, Garcia G, et al. Combination of 5- agacitidine and valproic acid in advanced solid cancers: a phase I study[J]. Proc Asco,2007, 25(8) : 3547.
  • 4Soriano AO, YangH, Faderl S, et al. Safety and caincal activity of the combination of 5 -agacitidine, valproic acid and alltrans retinoic acid in acutemydaid[J]. Blood, 2007, 110(7) : 2302 - 2308.
  • 5WIJERMANS P,LUBBERT M,VERHOEF G,et al.Low-dose5-Aza-2'-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients.Ann Hematol,2005,84(Suppl 13):9-17.
  • 6WIJERMANS P W,LUBBERT M,VERHOEF G,et al.An epigenetic approach to the treatment of advanced MDS;the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine(decitabine) in 177 patients[J].Ann Hematol,2005,84(Suppl 13):9-17.
  • 7Robertson K D,Wolffe A.DNA methylation in health and disease[J].Nat Rev Genet,2000,1:11-19.
  • 8Jones P A,Baylin SB.The epigenomics of cancer[J].Cell,2007,128:683-982.
  • 9Jones P A,Taylor SM.Cellular differentiation,cytidine anaogs and DNA methylation[J].Cell,1980,20:85-93.
  • 10Lakshmikuttyamma A,S A Scott,DeCoteau J F,et al.Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition[J].Oncogene,2010,29:576-588.

共引文献18

同被引文献50

  • 1梅振华,张虹,史登平,胡兵,方丽,李士平,周丽萍.三氧化二砷联合小剂量阿糖胞苷治疗骨髓增生异常综合征的临床观察[J].实用临床医学（江西）,2007,8(1):29-29. 被引量：3
  • 2陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:919.
  • 3第二届全国难治性白血病研讨会纪要.难治性白血病诊断标准.白血病淋巴瘤,2000,:63-63.
  • 4NIMER S D.Myelodysplastic syndromes[J].Blood,2008,111(10):4841-4851.
  • 5DELHOMMEAU F,DUPONT S,DELLA VALLE V,et al.Mutation in TET2 in myeloid cancers[J].N Engl J Med,2009,360(22):2289-2301.
  • 6TEFFERI A.Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms:JAK2,MPL,TET2,ASXL1,CBL,IDH and IKZF1[J].Leukemia,2010,24(6):1128-1138.
  • 7MOHR F,DOHNER K,BUSKE C,et al.TET Genes:new players in DNA demethylation and important determinants for stemness[J].Exp Hematol,2011,39(3):272-281.
  • 8ADEL-WAHAB O.Genetics of the myeloproliferative neoplasms[J].Curr Opin Hematol,2011,18(2):117-123.
  • 9LANGEMEIJERS M,KUIPER R P,BEREN M,et al.Acquired mutations in TET2 are common in myelodysplastic syndromes[J].Nat Genet,2009,41(7):838-842.
  • 10HAASE D,GERMING U,SCHANZ J,et al.New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:evidence from a core dataset of 2124[J].Blood,2007,110(13):4385-4395.

引证文献7

二级引证文献34

东南大学学报（医学版）
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部